Stacy Tessler Lindau1, Annie Dude, Natalia Gavrilova, Joscelyn N Hoffmann, L Philip Schumm, Martha K McClintock. 1. 1Departments of Ob/Gyn, Medicine (Geriatrics), and the Comprehensive Cancer Center, The University of Chicago, Chicago, IL 2Department of Ob/Gyn, The University of Chicago, Chicago, IL 3Institute for Mind and Biology, The University of Chicago, Chicago, IL 4Departments of Psychology and Comparative Human Development, The University of Chicago, Chicago, IL 5Department of Public Health Sciences, The University of Chicago, Chicago, IL.
Abstract
OBJECTIVE: This work aims to establish current population-based vaginal estrogenization norms for postmenopausal US women. METHODS: Using a US national probability sample of 868 postmenopausal women ages 57 to 85 years (mean age 67.6 ± 0.3 y, 21.6 ± 0.5 y since menopause), we calculated the epithelial maturation value (MV) generated from self-collected vaginal specimens and compared findings with historical clinical data. Linear and logistic regressions were used to describe the relationship between vaginal estrogenization and sociodemographic, physical, gynecologic, and sexual characteristics. RESULTS: Among postmenopausal women, mean MV was 46.6 ± 0.8 (SD 17.4, range 2.5-100) and stable across age groups. In every age group, vaginal estrogenization was higher among postmenopausal nonusers of hormone therapy (HT) in the 2005-2006 US cohort than reported for the 1960s Canadian clinical cohort. MV was also higher among women who used postmenopausal HT in the prior 12 months compared with those who did not (55.1 ± 1.2 vs 44.4 ± 0.9, P < 0.001). In multivariate analyses, HT use, obesity and African American race were each independently associated with higher MV. Overall, MV was not associated with sexual activity, but low MV was associated with vaginal dryness during intercourse among sexually active women. CONCLUSIONS: Compared to 1960s clinical data, current population estimates revealed higher vaginal estrogenization across all age groups and no decline with age. The strongest independent correlates of vaginal estrogenization in postmenopausal US women were current HT use, obesity, and African American race. Postmenopause, half of all women exhibit low vaginal estrogenization.
OBJECTIVE: This work aims to establish current population-based vaginal estrogenization norms for postmenopausal US women. METHODS: Using a US national probability sample of 868 postmenopausal women ages 57 to 85 years (mean age 67.6 ± 0.3 y, 21.6 ± 0.5 y since menopause), we calculated the epithelial maturation value (MV) generated from self-collected vaginal specimens and compared findings with historical clinical data. Linear and logistic regressions were used to describe the relationship between vaginal estrogenization and sociodemographic, physical, gynecologic, and sexual characteristics. RESULTS: Among postmenopausal women, mean MV was 46.6 ± 0.8 (SD 17.4, range 2.5-100) and stable across age groups. In every age group, vaginal estrogenization was higher among postmenopausal nonusers of hormone therapy (HT) in the 2005-2006 US cohort than reported for the 1960s Canadian clinical cohort. MV was also higher among women who used postmenopausal HT in the prior 12 months compared with those who did not (55.1 ± 1.2 vs 44.4 ± 0.9, P < 0.001). In multivariate analyses, HT use, obesity and African American race were each independently associated with higher MV. Overall, MV was not associated with sexual activity, but low MV was associated with vaginal dryness during intercourse among sexually active women. CONCLUSIONS: Compared to 1960s clinical data, current population estimates revealed higher vaginal estrogenization across all age groups and no decline with age. The strongest independent correlates of vaginal estrogenization in postmenopausal US women were current HT use, obesity, and African American race. Postmenopause, half of all women exhibit low vaginal estrogenization.
Authors: Stacy T Lindau; Joscelyn N Hoffmann; Katie Lundeen; Angela Jaszczak; Martha K McClintock; Jeanne A Jordan Journal: J Gerontol B Psychol Sci Soc Sci Date: 2009-02-09 Impact factor: 4.077
Authors: Veronica Wendy Setiawan; Christopher A Haiman; Frank Z Stanczyk; Loïc Le Marchand; Brian E Henderson Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-10 Impact factor: 4.254
Authors: Diana S M Buist; Katherine M Newton; Diana L Miglioretti; Kevin Beverly; Maureen T Connelly; Susan Andrade; Cynthia L Hartsfield; Feifei Wei; K Arnold Chan; Larry Kessler Journal: Obstet Gynecol Date: 2004-11 Impact factor: 7.661
Authors: Laura Baglietto; Dallas R English; John L Hopper; Robert J MacInnis; Howard A Morris; Wayne D Tilley; Kavitha Krishnan; Graham G Giles Journal: Breast Cancer Res Treat Date: 2008-05-29 Impact factor: 4.872
Authors: Mary M Hunter; Katherine A Guthrie; Joseph C Larson; Susan D Reed; Caroline M Mitchell; Susan J Diem; Andrea Z LaCroix; Alison J Huang Journal: J Sex Med Date: 2019-12-04 Impact factor: 3.802
Authors: Caroline M Mitchell; Susan D Reed; Susan Diem; Joseph C Larson; Katherine M Newton; Kristine E Ensrud; Andrea Z LaCroix; Bette Caan; Katherine A Guthrie Journal: JAMA Intern Med Date: 2018-05-01 Impact factor: 21.873
Authors: Patricia L Hudson; Wodan Ling; Michael C Wu; Matthew R Hayward; Alissa J Mitchell; Joseph Larson; Katherine A Guthrie; Susan D Reed; Douglas S Kwon; Caroline M Mitchell Journal: J Infect Dis Date: 2021-12-01 Impact factor: 5.226